Janux Therapeutics

JANX

Market cap $849M

SAN DIEGO--(BUSINESS WIRE)--Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and cohort expansion.

Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics (JANX 1.70%), exercised 16,665 options and immediately sold the resulting shares for a transaction value of approximately $501,000 on October 28, 2025, according to a recent SEC Form 4 filing.

Janux Therapeutics Inc. (NASDAQ: JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).

Shares of Janux Therapeutics slumped nearly 50% on Tuesday as investors reacted to limited disclosure in the company's early-stage study update for its prostate cancer treatment.

Janux Therapeutics stock crashed Tuesday on what one analyst called an "overreaction" to the company's prostate cancer treatment update.

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday.

Janux posts what it called ‘positive trial data' for its novel treatment in patients with late-stage prostate cancer.

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC.

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced it will host a virtual event on Monday, December 1, 2025, at 4:30 PM ET. David Campbell, Ph.D., President & Chief Execu.